nodes	percent_of_prediction	percent_of_DWPC	metapath
Ceftriaxone—ALB—hematologic cancer	0.224	1	CbGaD
Ceftriaxone—SLC22A8—Mercaptopurine—hematologic cancer	0.0744	0.274	CbGbCtD
Ceftriaxone—ALB—Imatinib—hematologic cancer	0.0436	0.161	CbGbCtD
Ceftriaxone—SLC22A11—Methotrexate—hematologic cancer	0.0418	0.154	CbGbCtD
Ceftriaxone—ALB—Prednisone—hematologic cancer	0.0288	0.106	CbGbCtD
Ceftriaxone—ALB—Irinotecan—hematologic cancer	0.0273	0.1	CbGbCtD
Ceftriaxone—SLC22A8—Methotrexate—hematologic cancer	0.0243	0.0896	CbGbCtD
Ceftriaxone—SLC22A6—Methotrexate—hematologic cancer	0.0169	0.0624	CbGbCtD
Ceftriaxone—ALB—Methotrexate—hematologic cancer	0.0144	0.0531	CbGbCtD
Ceftriaxone—GLUL—hematopoietic system—hematologic cancer	0.00135	0.137	CbGeAlD
Ceftriaxone—Cefazolin—PON1—hematologic cancer	0.0013	0.393	CrCbGaD
Ceftriaxone—GLUL—gonad—hematologic cancer	0.00103	0.104	CbGeAlD
Ceftriaxone—GLUL—blood—hematologic cancer	0.000895	0.0908	CbGeAlD
Ceftriaxone—GLUL—bone marrow—hematologic cancer	0.000866	0.0879	CbGeAlD
Ceftriaxone—SLC22A8—hematopoietic system—hematologic cancer	0.000804	0.0815	CbGeAlD
Ceftriaxone—GLUL—lung—hematologic cancer	0.000785	0.0796	CbGeAlD
Ceftriaxone—GLUL—testis—hematologic cancer	0.000741	0.0751	CbGeAlD
Ceftriaxone—GLUL—lymph node—hematologic cancer	0.000537	0.0545	CbGeAlD
Ceftriaxone—SLC22A8—blood—hematologic cancer	0.000532	0.054	CbGeAlD
Ceftriaxone—Cefdinir—MPO—hematologic cancer	0.000531	0.161	CrCbGaD
Ceftriaxone—SLC15A2—blood—hematologic cancer	0.000463	0.0469	CbGeAlD
Ceftriaxone—ALB—testis—hematologic cancer	0.000459	0.0465	CbGeAlD
Ceftriaxone—SLC15A2—lung—hematologic cancer	0.000406	0.0411	CbGeAlD
Ceftriaxone—Cefotetan—ALB—hematologic cancer	0.000394	0.119	CrCbGaD
Ceftriaxone—SLC15A2—testis—hematologic cancer	0.000383	0.0388	CbGeAlD
Ceftriaxone—Cefpiramide—ALB—hematologic cancer	0.000343	0.104	CrCbGaD
Ceftriaxone—ALB—lymph node—hematologic cancer	0.000332	0.0337	CbGeAlD
Ceftriaxone—Cefonicid—ALB—hematologic cancer	0.000298	0.0903	CrCbGaD
Ceftriaxone—SLC15A2—lymph node—hematologic cancer	0.000277	0.0281	CbGeAlD
Ceftriaxone—Cefoperazone—ALB—hematologic cancer	0.000176	0.0532	CrCbGaD
Ceftriaxone—Cefazolin—ALB—hematologic cancer	0.000145	0.0437	CrCbGaD
Ceftriaxone—Cefalotin—ALB—hematologic cancer	0.00012	0.0363	CrCbGaD
Ceftriaxone—Dizziness—Vincristine—hematologic cancer	6.9e-05	0.000163	CcSEcCtD
Ceftriaxone—Rash—Carmustine—hematologic cancer	6.89e-05	0.000163	CcSEcCtD
Ceftriaxone—Ill-defined disorder—Prednisone—hematologic cancer	6.89e-05	0.000163	CcSEcCtD
Ceftriaxone—Dermatitis—Carmustine—hematologic cancer	6.88e-05	0.000163	CcSEcCtD
Ceftriaxone—Vomiting—Alitretinoin—hematologic cancer	6.88e-05	0.000163	CcSEcCtD
Ceftriaxone—Paraesthesia—Triamcinolone—hematologic cancer	6.88e-05	0.000163	CcSEcCtD
Ceftriaxone—Feeling abnormal—Prednisolone—hematologic cancer	6.87e-05	0.000163	CcSEcCtD
Ceftriaxone—Anaemia—Prednisone—hematologic cancer	6.86e-05	0.000162	CcSEcCtD
Ceftriaxone—Headache—Carmustine—hematologic cancer	6.85e-05	0.000162	CcSEcCtD
Ceftriaxone—Rash—Alitretinoin—hematologic cancer	6.83e-05	0.000162	CcSEcCtD
Ceftriaxone—Agitation—Prednisone—hematologic cancer	6.82e-05	0.000161	CcSEcCtD
Ceftriaxone—Dermatitis—Alitretinoin—hematologic cancer	6.82e-05	0.000161	CcSEcCtD
Ceftriaxone—Stevens-Johnson syndrome—Doxorubicin—hematologic cancer	6.81e-05	0.000161	CcSEcCtD
Ceftriaxone—Thrombocytopenia—Betamethasone—hematologic cancer	6.81e-05	0.000161	CcSEcCtD
Ceftriaxone—Thrombocytopenia—Dexamethasone—hematologic cancer	6.81e-05	0.000161	CcSEcCtD
Ceftriaxone—Vomiting—Ifosfamide—hematologic cancer	6.8e-05	0.000161	CcSEcCtD
Ceftriaxone—Hypersensitivity—Cisplatin—hematologic cancer	6.8e-05	0.000161	CcSEcCtD
Ceftriaxone—Headache—Alitretinoin—hematologic cancer	6.78e-05	0.000161	CcSEcCtD
Ceftriaxone—Diarrhoea—Gemcitabine—hematologic cancer	6.77e-05	0.00016	CcSEcCtD
Ceftriaxone—Nausea—Thalidomide—hematologic cancer	6.76e-05	0.00016	CcSEcCtD
Ceftriaxone—Renal failure—Doxorubicin—hematologic cancer	6.76e-05	0.00016	CcSEcCtD
Ceftriaxone—Dyspepsia—Triamcinolone—hematologic cancer	6.75e-05	0.00016	CcSEcCtD
Ceftriaxone—Rash—Ifosfamide—hematologic cancer	6.75e-05	0.00016	CcSEcCtD
Ceftriaxone—Dermatitis—Ifosfamide—hematologic cancer	6.74e-05	0.00016	CcSEcCtD
Ceftriaxone—Erythema multiforme—Methotrexate—hematologic cancer	6.74e-05	0.00016	CcSEcCtD
Ceftriaxone—Hyperhidrosis—Betamethasone—hematologic cancer	6.72e-05	0.000159	CcSEcCtD
Ceftriaxone—Hyperhidrosis—Dexamethasone—hematologic cancer	6.72e-05	0.000159	CcSEcCtD
Ceftriaxone—Dizziness—Irinotecan—hematologic cancer	6.72e-05	0.000159	CcSEcCtD
Ceftriaxone—Urticaria—Etoposide—hematologic cancer	6.71e-05	0.000159	CcSEcCtD
Ceftriaxone—Haemoglobin—Epirubicin—hematologic cancer	6.7e-05	0.000159	CcSEcCtD
Ceftriaxone—Stomatitis—Doxorubicin—hematologic cancer	6.7e-05	0.000159	CcSEcCtD
Ceftriaxone—Jaundice—Doxorubicin—hematologic cancer	6.7e-05	0.000159	CcSEcCtD
Ceftriaxone—Malaise—Prednisone—hematologic cancer	6.69e-05	0.000158	CcSEcCtD
Ceftriaxone—Abdominal pain—Etoposide—hematologic cancer	6.68e-05	0.000158	CcSEcCtD
Ceftriaxone—Body temperature increased—Etoposide—hematologic cancer	6.68e-05	0.000158	CcSEcCtD
Ceftriaxone—Haemorrhage—Epirubicin—hematologic cancer	6.67e-05	0.000158	CcSEcCtD
Ceftriaxone—Vomiting—Vincristine—hematologic cancer	6.63e-05	0.000157	CcSEcCtD
Ceftriaxone—Urticaria—Prednisolone—hematologic cancer	6.62e-05	0.000157	CcSEcCtD
Ceftriaxone—Rash—Vincristine—hematologic cancer	6.58e-05	0.000156	CcSEcCtD
Ceftriaxone—Dermatitis—Vincristine—hematologic cancer	6.57e-05	0.000156	CcSEcCtD
Ceftriaxone—Pain—Triamcinolone—hematologic cancer	6.55e-05	0.000155	CcSEcCtD
Ceftriaxone—Haematuria—Doxorubicin—hematologic cancer	6.55e-05	0.000155	CcSEcCtD
Ceftriaxone—Headache—Vincristine—hematologic cancer	6.54e-05	0.000155	CcSEcCtD
Ceftriaxone—Nausea—Carmustine—hematologic cancer	6.49e-05	0.000154	CcSEcCtD
Ceftriaxone—Epistaxis—Doxorubicin—hematologic cancer	6.48e-05	0.000153	CcSEcCtD
Ceftriaxone—Vomiting—Mitoxantrone—hematologic cancer	6.46e-05	0.000153	CcSEcCtD
Ceftriaxone—Vomiting—Irinotecan—hematologic cancer	6.46e-05	0.000153	CcSEcCtD
Ceftriaxone—Nausea—Alitretinoin—hematologic cancer	6.43e-05	0.000152	CcSEcCtD
Ceftriaxone—Convulsion—Prednisone—hematologic cancer	6.43e-05	0.000152	CcSEcCtD
Ceftriaxone—Agranulocytosis—Doxorubicin—hematologic cancer	6.41e-05	0.000152	CcSEcCtD
Ceftriaxone—Rash—Irinotecan—hematologic cancer	6.41e-05	0.000152	CcSEcCtD
Ceftriaxone—Rash—Mitoxantrone—hematologic cancer	6.41e-05	0.000152	CcSEcCtD
Ceftriaxone—Dermatitis—Irinotecan—hematologic cancer	6.4e-05	0.000152	CcSEcCtD
Ceftriaxone—Dermatitis—Mitoxantrone—hematologic cancer	6.4e-05	0.000152	CcSEcCtD
Ceftriaxone—Chills—Methotrexate—hematologic cancer	6.39e-05	0.000151	CcSEcCtD
Ceftriaxone—Headache—Irinotecan—hematologic cancer	6.36e-05	0.000151	CcSEcCtD
Ceftriaxone—Headache—Mitoxantrone—hematologic cancer	6.36e-05	0.000151	CcSEcCtD
Ceftriaxone—Nausea—Ifosfamide—hematologic cancer	6.36e-05	0.00015	CcSEcCtD
Ceftriaxone—Feeling abnormal—Triamcinolone—hematologic cancer	6.32e-05	0.00015	CcSEcCtD
Ceftriaxone—Diarrhoea—Cisplatin—hematologic cancer	6.31e-05	0.000149	CcSEcCtD
Ceftriaxone—Erythema multiforme—Epirubicin—hematologic cancer	6.3e-05	0.000149	CcSEcCtD
Ceftriaxone—Vomiting—Gemcitabine—hematologic cancer	6.29e-05	0.000149	CcSEcCtD
Ceftriaxone—Paraesthesia—Dexamethasone—hematologic cancer	6.24e-05	0.000148	CcSEcCtD
Ceftriaxone—Paraesthesia—Betamethasone—hematologic cancer	6.24e-05	0.000148	CcSEcCtD
Ceftriaxone—Discomfort—Prednisone—hematologic cancer	6.24e-05	0.000148	CcSEcCtD
Ceftriaxone—Rash—Gemcitabine—hematologic cancer	6.24e-05	0.000148	CcSEcCtD
Ceftriaxone—Dermatitis—Gemcitabine—hematologic cancer	6.23e-05	0.000148	CcSEcCtD
Ceftriaxone—Hypersensitivity—Etoposide—hematologic cancer	6.23e-05	0.000147	CcSEcCtD
Ceftriaxone—Haemoglobin—Doxorubicin—hematologic cancer	6.2e-05	0.000147	CcSEcCtD
Ceftriaxone—Headache—Gemcitabine—hematologic cancer	6.2e-05	0.000147	CcSEcCtD
Ceftriaxone—Nausea—Vincristine—hematologic cancer	6.2e-05	0.000147	CcSEcCtD
Ceftriaxone—Flushing—Epirubicin—hematologic cancer	6.19e-05	0.000147	CcSEcCtD
Ceftriaxone—Haemorrhage—Doxorubicin—hematologic cancer	6.17e-05	0.000146	CcSEcCtD
Ceftriaxone—Hypersensitivity—Prednisolone—hematologic cancer	6.14e-05	0.000145	CcSEcCtD
Ceftriaxone—Dyspepsia—Dexamethasone—hematologic cancer	6.12e-05	0.000145	CcSEcCtD
Ceftriaxone—Dyspepsia—Betamethasone—hematologic cancer	6.12e-05	0.000145	CcSEcCtD
Ceftriaxone—Urticaria—Triamcinolone—hematologic cancer	6.09e-05	0.000144	CcSEcCtD
Ceftriaxone—Dysgeusia—Methotrexate—hematologic cancer	6.07e-05	0.000144	CcSEcCtD
Ceftriaxone—Body temperature increased—Triamcinolone—hematologic cancer	6.06e-05	0.000143	CcSEcCtD
Ceftriaxone—Anaphylactic shock—Prednisone—hematologic cancer	6.06e-05	0.000143	CcSEcCtD
Ceftriaxone—Oedema—Prednisone—hematologic cancer	6.06e-05	0.000143	CcSEcCtD
Ceftriaxone—Nausea—Mitoxantrone—hematologic cancer	6.03e-05	0.000143	CcSEcCtD
Ceftriaxone—Nausea—Irinotecan—hematologic cancer	6.03e-05	0.000143	CcSEcCtD
Ceftriaxone—Infection—Prednisone—hematologic cancer	6.02e-05	0.000142	CcSEcCtD
Ceftriaxone—Chills—Epirubicin—hematologic cancer	5.98e-05	0.000142	CcSEcCtD
Ceftriaxone—Pruritus—Etoposide—hematologic cancer	5.98e-05	0.000142	CcSEcCtD
Ceftriaxone—Pain—Betamethasone—hematologic cancer	5.95e-05	0.000141	CcSEcCtD
Ceftriaxone—Pain—Dexamethasone—hematologic cancer	5.95e-05	0.000141	CcSEcCtD
Ceftriaxone—Nausea—Gemcitabine—hematologic cancer	5.88e-05	0.000139	CcSEcCtD
Ceftriaxone—Vomiting—Cisplatin—hematologic cancer	5.86e-05	0.000139	CcSEcCtD
Ceftriaxone—Hyperhidrosis—Prednisone—hematologic cancer	5.86e-05	0.000139	CcSEcCtD
Ceftriaxone—Erythema multiforme—Doxorubicin—hematologic cancer	5.83e-05	0.000138	CcSEcCtD
Ceftriaxone—Rash—Cisplatin—hematologic cancer	5.82e-05	0.000138	CcSEcCtD
Ceftriaxone—Dermatitis—Cisplatin—hematologic cancer	5.81e-05	0.000138	CcSEcCtD
Ceftriaxone—Diarrhoea—Etoposide—hematologic cancer	5.78e-05	0.000137	CcSEcCtD
Ceftriaxone—Ill-defined disorder—Methotrexate—hematologic cancer	5.75e-05	0.000136	CcSEcCtD
Ceftriaxone—Anaemia—Methotrexate—hematologic cancer	5.73e-05	0.000136	CcSEcCtD
Ceftriaxone—Feeling abnormal—Dexamethasone—hematologic cancer	5.73e-05	0.000136	CcSEcCtD
Ceftriaxone—Feeling abnormal—Betamethasone—hematologic cancer	5.73e-05	0.000136	CcSEcCtD
Ceftriaxone—Flushing—Doxorubicin—hematologic cancer	5.73e-05	0.000136	CcSEcCtD
Ceftriaxone—Flatulence—Epirubicin—hematologic cancer	5.72e-05	0.000135	CcSEcCtD
Ceftriaxone—Gastrointestinal pain—Dexamethasone—hematologic cancer	5.69e-05	0.000135	CcSEcCtD
Ceftriaxone—Gastrointestinal pain—Betamethasone—hematologic cancer	5.69e-05	0.000135	CcSEcCtD
Ceftriaxone—Dysgeusia—Epirubicin—hematologic cancer	5.68e-05	0.000135	CcSEcCtD
Ceftriaxone—Hypersensitivity—Triamcinolone—hematologic cancer	5.65e-05	0.000134	CcSEcCtD
Ceftriaxone—Malaise—Methotrexate—hematologic cancer	5.59e-05	0.000132	CcSEcCtD
Ceftriaxone—Dizziness—Etoposide—hematologic cancer	5.59e-05	0.000132	CcSEcCtD
Ceftriaxone—ALB—Folate Metabolism—IFNG—hematologic cancer	5.58e-05	0.000805	CbGpPWpGaD
Ceftriaxone—SLC15A2—Transmembrane transport of small molecules—CYCS—hematologic cancer	5.56e-05	0.000801	CbGpPWpGaD
Ceftriaxone—Leukopenia—Methotrexate—hematologic cancer	5.55e-05	0.000131	CcSEcCtD
Ceftriaxone—ALB—SLC-mediated transmembrane transport—NUP98—hematologic cancer	5.54e-05	0.000799	CbGpPWpGaD
Ceftriaxone—ALB—Platelet activation, signaling and aggregation—SPARC—hematologic cancer	5.54e-05	0.000799	CbGpPWpGaD
Ceftriaxone—Chills—Doxorubicin—hematologic cancer	5.54e-05	0.000131	CcSEcCtD
Ceftriaxone—Urticaria—Dexamethasone—hematologic cancer	5.52e-05	0.000131	CcSEcCtD
Ceftriaxone—Urticaria—Betamethasone—hematologic cancer	5.52e-05	0.000131	CcSEcCtD
Ceftriaxone—Dizziness—Prednisolone—hematologic cancer	5.51e-05	0.000131	CcSEcCtD
Ceftriaxone—ALB—Hemostasis—ATP1B1—hematologic cancer	5.5e-05	0.000793	CbGpPWpGaD
Ceftriaxone—Abdominal pain—Dexamethasone—hematologic cancer	5.5e-05	0.00013	CcSEcCtD
Ceftriaxone—Body temperature increased—Dexamethasone—hematologic cancer	5.5e-05	0.00013	CcSEcCtD
Ceftriaxone—Abdominal pain—Betamethasone—hematologic cancer	5.5e-05	0.00013	CcSEcCtD
Ceftriaxone—Body temperature increased—Betamethasone—hematologic cancer	5.5e-05	0.00013	CcSEcCtD
Ceftriaxone—Nausea—Cisplatin—hematologic cancer	5.48e-05	0.00013	CcSEcCtD
Ceftriaxone—SLC22A8—Transmembrane transport of small molecules—TFRC—hematologic cancer	5.46e-05	0.000788	CbGpPWpGaD
Ceftriaxone—ALB—Transmembrane transport of small molecules—S100A10—hematologic cancer	5.45e-05	0.000785	CbGpPWpGaD
Ceftriaxone—Paraesthesia—Prednisone—hematologic cancer	5.44e-05	0.000129	CcSEcCtD
Ceftriaxone—Pruritus—Triamcinolone—hematologic cancer	5.42e-05	0.000128	CcSEcCtD
Ceftriaxone—SLC22A6—Transmembrane transport of small molecules—NUP98—hematologic cancer	5.42e-05	0.000781	CbGpPWpGaD
Ceftriaxone—Ill-defined disorder—Epirubicin—hematologic cancer	5.39e-05	0.000128	CcSEcCtD
Ceftriaxone—Convulsion—Methotrexate—hematologic cancer	5.37e-05	0.000127	CcSEcCtD
Ceftriaxone—Vomiting—Etoposide—hematologic cancer	5.37e-05	0.000127	CcSEcCtD
Ceftriaxone—ALB—Platelet activation, signaling and aggregation—LCK—hematologic cancer	5.37e-05	0.000774	CbGpPWpGaD
Ceftriaxone—Anaemia—Epirubicin—hematologic cancer	5.36e-05	0.000127	CcSEcCtD
Ceftriaxone—ALB—SLC-mediated transmembrane transport—NUP214—hematologic cancer	5.34e-05	0.00077	CbGpPWpGaD
Ceftriaxone—Agitation—Epirubicin—hematologic cancer	5.33e-05	0.000126	CcSEcCtD
Ceftriaxone—Dyspepsia—Prednisone—hematologic cancer	5.33e-05	0.000126	CcSEcCtD
Ceftriaxone—Rash—Etoposide—hematologic cancer	5.33e-05	0.000126	CcSEcCtD
Ceftriaxone—ALB—Metabolism of lipids and lipoproteins—GBA—hematologic cancer	5.32e-05	0.000768	CbGpPWpGaD
Ceftriaxone—Dermatitis—Etoposide—hematologic cancer	5.32e-05	0.000126	CcSEcCtD
Ceftriaxone—SLC15A1—SLC-mediated transmembrane transport—ALB—hematologic cancer	5.3e-05	0.000763	CbGpPWpGaD
Ceftriaxone—Headache—Etoposide—hematologic cancer	5.29e-05	0.000125	CcSEcCtD
Ceftriaxone—Flatulence—Doxorubicin—hematologic cancer	5.29e-05	0.000125	CcSEcCtD
Ceftriaxone—SLC22A6—Transmembrane transport of small molecules—ADCY7—hematologic cancer	5.26e-05	0.000758	CbGpPWpGaD
Ceftriaxone—Dysgeusia—Doxorubicin—hematologic cancer	5.26e-05	0.000125	CcSEcCtD
Ceftriaxone—Rash—Prednisolone—hematologic cancer	5.26e-05	0.000124	CcSEcCtD
Ceftriaxone—Dermatitis—Prednisolone—hematologic cancer	5.25e-05	0.000124	CcSEcCtD
Ceftriaxone—Malaise—Epirubicin—hematologic cancer	5.23e-05	0.000124	CcSEcCtD
Ceftriaxone—SLC22A6—Transmembrane transport of small molecules—NUP214—hematologic cancer	5.22e-05	0.000753	CbGpPWpGaD
Ceftriaxone—Headache—Prednisolone—hematologic cancer	5.22e-05	0.000124	CcSEcCtD
Ceftriaxone—ALB—Selenium Micronutrient Network—CCL2—hematologic cancer	5.22e-05	0.000752	CbGpPWpGaD
Ceftriaxone—Discomfort—Methotrexate—hematologic cancer	5.22e-05	0.000124	CcSEcCtD
Ceftriaxone—ALB—Hemostasis—GATA1—hematologic cancer	5.21e-05	0.000751	CbGpPWpGaD
Ceftriaxone—Leukopenia—Epirubicin—hematologic cancer	5.2e-05	0.000123	CcSEcCtD
Ceftriaxone—ALB—Platelet activation, signaling and aggregation—HSPA5—hematologic cancer	5.19e-05	0.000747	CbGpPWpGaD
Ceftriaxone—SLC15A1—Transmembrane transport of small molecules—CYCS—hematologic cancer	5.16e-05	0.000743	CbGpPWpGaD
Ceftriaxone—Palpitations—Epirubicin—hematologic cancer	5.13e-05	0.000121	CcSEcCtD
Ceftriaxone—SLC22A6—Transmembrane transport of small molecules—ABCG2—hematologic cancer	5.12e-05	0.000738	CbGpPWpGaD
Ceftriaxone—ALB—Platelet activation, signaling and aggregation—PRKCZ—hematologic cancer	5.11e-05	0.000737	CbGpPWpGaD
Ceftriaxone—Dizziness—Triamcinolone—hematologic cancer	5.07e-05	0.00012	CcSEcCtD
Ceftriaxone—ALB—Transmembrane transport of small molecules—SLC35B2—hematologic cancer	5.06e-05	0.00073	CbGpPWpGaD
Ceftriaxone—Anaphylactic shock—Methotrexate—hematologic cancer	5.06e-05	0.00012	CcSEcCtD
Ceftriaxone—Convulsion—Epirubicin—hematologic cancer	5.03e-05	0.000119	CcSEcCtD
Ceftriaxone—Infection—Methotrexate—hematologic cancer	5.03e-05	0.000119	CcSEcCtD
Ceftriaxone—Nausea—Etoposide—hematologic cancer	5.02e-05	0.000119	CcSEcCtD
Ceftriaxone—SLC22A11—Transmembrane transport of small molecules—ABCB1—hematologic cancer	5.02e-05	0.000723	CbGpPWpGaD
Ceftriaxone—Feeling abnormal—Prednisone—hematologic cancer	4.99e-05	0.000118	CcSEcCtD
Ceftriaxone—GLUL—Metabolism—GSTP1—hematologic cancer	4.98e-05	0.000718	CbGpPWpGaD
Ceftriaxone—Ill-defined disorder—Doxorubicin—hematologic cancer	4.98e-05	0.000118	CcSEcCtD
Ceftriaxone—ALB—Folate Metabolism—IL1B—hematologic cancer	4.98e-05	0.000718	CbGpPWpGaD
Ceftriaxone—Anaemia—Doxorubicin—hematologic cancer	4.96e-05	0.000118	CcSEcCtD
Ceftriaxone—ALB—Folate Metabolism—IL2—hematologic cancer	4.96e-05	0.000715	CbGpPWpGaD
Ceftriaxone—Thrombocytopenia—Methotrexate—hematologic cancer	4.96e-05	0.000117	CcSEcCtD
Ceftriaxone—Gastrointestinal pain—Prednisone—hematologic cancer	4.95e-05	0.000117	CcSEcCtD
Ceftriaxone—Nausea—Prednisolone—hematologic cancer	4.95e-05	0.000117	CcSEcCtD
Ceftriaxone—Agitation—Doxorubicin—hematologic cancer	4.94e-05	0.000117	CcSEcCtD
Ceftriaxone—Pruritus—Betamethasone—hematologic cancer	4.92e-05	0.000117	CcSEcCtD
Ceftriaxone—Pruritus—Dexamethasone—hematologic cancer	4.92e-05	0.000117	CcSEcCtD
Ceftriaxone—Hyperhidrosis—Methotrexate—hematologic cancer	4.89e-05	0.000116	CcSEcCtD
Ceftriaxone—Discomfort—Epirubicin—hematologic cancer	4.88e-05	0.000116	CcSEcCtD
Ceftriaxone—Vomiting—Triamcinolone—hematologic cancer	4.87e-05	0.000115	CcSEcCtD
Ceftriaxone—Malaise—Doxorubicin—hematologic cancer	4.84e-05	0.000115	CcSEcCtD
Ceftriaxone—Rash—Triamcinolone—hematologic cancer	4.83e-05	0.000114	CcSEcCtD
Ceftriaxone—Dermatitis—Triamcinolone—hematologic cancer	4.83e-05	0.000114	CcSEcCtD
Ceftriaxone—Urticaria—Prednisone—hematologic cancer	4.81e-05	0.000114	CcSEcCtD
Ceftriaxone—Leukopenia—Doxorubicin—hematologic cancer	4.81e-05	0.000114	CcSEcCtD
Ceftriaxone—Headache—Triamcinolone—hematologic cancer	4.8e-05	0.000114	CcSEcCtD
Ceftriaxone—Abdominal pain—Prednisone—hematologic cancer	4.79e-05	0.000113	CcSEcCtD
Ceftriaxone—Body temperature increased—Prednisone—hematologic cancer	4.79e-05	0.000113	CcSEcCtD
Ceftriaxone—ALB—Hemostasis—ANXA2—hematologic cancer	4.77e-05	0.000687	CbGpPWpGaD
Ceftriaxone—ALB—Transmembrane transport of small molecules—ATP1B1—hematologic cancer	4.76e-05	0.000686	CbGpPWpGaD
Ceftriaxone—Diarrhoea—Dexamethasone—hematologic cancer	4.76e-05	0.000113	CcSEcCtD
Ceftriaxone—Diarrhoea—Betamethasone—hematologic cancer	4.76e-05	0.000113	CcSEcCtD
Ceftriaxone—Palpitations—Doxorubicin—hematologic cancer	4.75e-05	0.000112	CcSEcCtD
Ceftriaxone—Oedema—Epirubicin—hematologic cancer	4.74e-05	0.000112	CcSEcCtD
Ceftriaxone—Anaphylactic shock—Epirubicin—hematologic cancer	4.74e-05	0.000112	CcSEcCtD
Ceftriaxone—GLUL—Metabolism—ABCB1—hematologic cancer	4.72e-05	0.00068	CbGpPWpGaD
Ceftriaxone—SLC22A8—SLC-mediated transmembrane transport—ALB—hematologic cancer	4.71e-05	0.000679	CbGpPWpGaD
Ceftriaxone—Infection—Epirubicin—hematologic cancer	4.71e-05	0.000111	CcSEcCtD
Ceftriaxone—Convulsion—Doxorubicin—hematologic cancer	4.65e-05	0.00011	CcSEcCtD
Ceftriaxone—Thrombocytopenia—Epirubicin—hematologic cancer	4.64e-05	0.00011	CcSEcCtD
Ceftriaxone—SLC15A2—Transmembrane transport of small molecules—ABCB1—hematologic cancer	4.64e-05	0.000668	CbGpPWpGaD
Ceftriaxone—Dizziness—Betamethasone—hematologic cancer	4.6e-05	0.000109	CcSEcCtD
Ceftriaxone—Dizziness—Dexamethasone—hematologic cancer	4.6e-05	0.000109	CcSEcCtD
Ceftriaxone—ALB—Platelet activation, signaling and aggregation—IL3—hematologic cancer	4.59e-05	0.000662	CbGpPWpGaD
Ceftriaxone—SLC22A8—Transmembrane transport of small molecules—CYCS—hematologic cancer	4.59e-05	0.000661	CbGpPWpGaD
Ceftriaxone—GLUL—Metabolism—GSTM1—hematologic cancer	4.58e-05	0.00066	CbGpPWpGaD
Ceftriaxone—GLUL—Metabolism—NCOR1—hematologic cancer	4.58e-05	0.00066	CbGpPWpGaD
Ceftriaxone—Hyperhidrosis—Epirubicin—hematologic cancer	4.58e-05	0.000108	CcSEcCtD
Ceftriaxone—SLC22A6—Transmembrane transport of small molecules—TFRC—hematologic cancer	4.56e-05	0.000657	CbGpPWpGaD
Ceftriaxone—Nausea—Triamcinolone—hematologic cancer	4.55e-05	0.000108	CcSEcCtD
Ceftriaxone—Paraesthesia—Methotrexate—hematologic cancer	4.55e-05	0.000108	CcSEcCtD
Ceftriaxone—Discomfort—Doxorubicin—hematologic cancer	4.52e-05	0.000107	CcSEcCtD
Ceftriaxone—ALB—Platelet activation, signaling and aggregation—PTPN1—hematologic cancer	4.52e-05	0.000651	CbGpPWpGaD
Ceftriaxone—ALB—Transmembrane transport of small molecules—SLC26A4—hematologic cancer	4.51e-05	0.00065	CbGpPWpGaD
Ceftriaxone—Hypersensitivity—Prednisone—hematologic cancer	4.46e-05	0.000106	CcSEcCtD
Ceftriaxone—Dyspepsia—Methotrexate—hematologic cancer	4.46e-05	0.000106	CcSEcCtD
Ceftriaxone—ALB—Platelet activation, signaling and aggregation—RASGRP1—hematologic cancer	4.44e-05	0.000641	CbGpPWpGaD
Ceftriaxone—ALB—Vitamin B12 Metabolism—TNF—hematologic cancer	4.44e-05	0.00064	CbGpPWpGaD
Ceftriaxone—ALB—Selenium Micronutrient Network—IFNG—hematologic cancer	4.44e-05	0.000639	CbGpPWpGaD
Ceftriaxone—ALB—Hemostasis—GNA13—hematologic cancer	4.43e-05	0.000639	CbGpPWpGaD
Ceftriaxone—ALB—Platelet activation, signaling and aggregation—SYK—hematologic cancer	4.43e-05	0.000639	CbGpPWpGaD
Ceftriaxone—Vomiting—Dexamethasone—hematologic cancer	4.42e-05	0.000105	CcSEcCtD
Ceftriaxone—Vomiting—Betamethasone—hematologic cancer	4.42e-05	0.000105	CcSEcCtD
Ceftriaxone—Rash—Dexamethasone—hematologic cancer	4.39e-05	0.000104	CcSEcCtD
Ceftriaxone—Rash—Betamethasone—hematologic cancer	4.39e-05	0.000104	CcSEcCtD
Ceftriaxone—Anaphylactic shock—Doxorubicin—hematologic cancer	4.38e-05	0.000104	CcSEcCtD
Ceftriaxone—Oedema—Doxorubicin—hematologic cancer	4.38e-05	0.000104	CcSEcCtD
Ceftriaxone—Dermatitis—Dexamethasone—hematologic cancer	4.38e-05	0.000104	CcSEcCtD
Ceftriaxone—Dermatitis—Betamethasone—hematologic cancer	4.38e-05	0.000104	CcSEcCtD
Ceftriaxone—Headache—Dexamethasone—hematologic cancer	4.36e-05	0.000103	CcSEcCtD
Ceftriaxone—Headache—Betamethasone—hematologic cancer	4.36e-05	0.000103	CcSEcCtD
Ceftriaxone—Infection—Doxorubicin—hematologic cancer	4.35e-05	0.000103	CcSEcCtD
Ceftriaxone—ALB—Metabolism of lipids and lipoproteins—FHL2—hematologic cancer	4.34e-05	0.000626	CbGpPWpGaD
Ceftriaxone—Pain—Methotrexate—hematologic cancer	4.33e-05	0.000102	CcSEcCtD
Ceftriaxone—SLC15A1—Transmembrane transport of small molecules—ABCB1—hematologic cancer	4.3e-05	0.00062	CbGpPWpGaD
Ceftriaxone—Thrombocytopenia—Doxorubicin—hematologic cancer	4.29e-05	0.000102	CcSEcCtD
Ceftriaxone—Pruritus—Prednisone—hematologic cancer	4.29e-05	0.000101	CcSEcCtD
Ceftriaxone—Paraesthesia—Epirubicin—hematologic cancer	4.25e-05	0.000101	CcSEcCtD
Ceftriaxone—Hyperhidrosis—Doxorubicin—hematologic cancer	4.24e-05	0.0001	CcSEcCtD
Ceftriaxone—ALB—Hemostasis—ITGAX—hematologic cancer	4.23e-05	0.00061	CbGpPWpGaD
Ceftriaxone—ALB—Hemostasis—JAK3—hematologic cancer	4.23e-05	0.00061	CbGpPWpGaD
Ceftriaxone—Feeling abnormal—Methotrexate—hematologic cancer	4.17e-05	9.88e-05	CcSEcCtD
Ceftriaxone—Dyspepsia—Epirubicin—hematologic cancer	4.17e-05	9.87e-05	CcSEcCtD
Ceftriaxone—ALB—Hemostasis—CD9—hematologic cancer	4.17e-05	0.000601	CbGpPWpGaD
Ceftriaxone—ALB—Hemostasis—F3—hematologic cancer	4.17e-05	0.000601	CbGpPWpGaD
Ceftriaxone—Diarrhoea—Prednisone—hematologic cancer	4.14e-05	9.81e-05	CcSEcCtD
Ceftriaxone—Gastrointestinal pain—Methotrexate—hematologic cancer	4.14e-05	9.8e-05	CcSEcCtD
Ceftriaxone—Nausea—Dexamethasone—hematologic cancer	4.13e-05	9.78e-05	CcSEcCtD
Ceftriaxone—Nausea—Betamethasone—hematologic cancer	4.13e-05	9.78e-05	CcSEcCtD
Ceftriaxone—ALB—Transmembrane transport of small molecules—ATP4A—hematologic cancer	4.13e-05	0.000595	CbGpPWpGaD
Ceftriaxone—ALB—Transmembrane transport of small molecules—SGK1—hematologic cancer	4.13e-05	0.000595	CbGpPWpGaD
Ceftriaxone—ALB—Transmembrane transport of small molecules—ANXA2—hematologic cancer	4.13e-05	0.000595	CbGpPWpGaD
Ceftriaxone—ALB—Hemostasis—SELL—hematologic cancer	4.05e-05	0.000584	CbGpPWpGaD
Ceftriaxone—Pain—Epirubicin—hematologic cancer	4.05e-05	9.59e-05	CcSEcCtD
Ceftriaxone—GLUL—Metabolism—MTHFR—hematologic cancer	4.05e-05	0.000584	CbGpPWpGaD
Ceftriaxone—Urticaria—Methotrexate—hematologic cancer	4.02e-05	9.52e-05	CcSEcCtD
Ceftriaxone—Dizziness—Prednisone—hematologic cancer	4.01e-05	9.48e-05	CcSEcCtD
Ceftriaxone—Body temperature increased—Methotrexate—hematologic cancer	4e-05	9.47e-05	CcSEcCtD
Ceftriaxone—Abdominal pain—Methotrexate—hematologic cancer	4e-05	9.47e-05	CcSEcCtD
Ceftriaxone—ALB—Platelet activation, signaling and aggregation—GRB2—hematologic cancer	4e-05	0.000576	CbGpPWpGaD
Ceftriaxone—ALB—Platelet activation, signaling and aggregation—PDGFA—hematologic cancer	3.99e-05	0.000575	CbGpPWpGaD
Ceftriaxone—ALB—Selenium Micronutrient Network—IL1B—hematologic cancer	3.96e-05	0.00057	CbGpPWpGaD
Ceftriaxone—ALB—Hemostasis—IL3RA—hematologic cancer	3.95e-05	0.000569	CbGpPWpGaD
Ceftriaxone—Paraesthesia—Doxorubicin—hematologic cancer	3.94e-05	9.32e-05	CcSEcCtD
Ceftriaxone—SLC22A6—SLC-mediated transmembrane transport—ALB—hematologic cancer	3.93e-05	0.000567	CbGpPWpGaD
Ceftriaxone—Feeling abnormal—Epirubicin—hematologic cancer	3.9e-05	9.24e-05	CcSEcCtD
Ceftriaxone—Gastrointestinal pain—Epirubicin—hematologic cancer	3.87e-05	9.17e-05	CcSEcCtD
Ceftriaxone—Dyspepsia—Doxorubicin—hematologic cancer	3.86e-05	9.14e-05	CcSEcCtD
Ceftriaxone—Vomiting—Prednisone—hematologic cancer	3.85e-05	9.12e-05	CcSEcCtD
Ceftriaxone—SLC22A6—Transmembrane transport of small molecules—CYCS—hematologic cancer	3.83e-05	0.000552	CbGpPWpGaD
Ceftriaxone—SLC22A8—Transmembrane transport of small molecules—ABCB1—hematologic cancer	3.83e-05	0.000551	CbGpPWpGaD
Ceftriaxone—Rash—Prednisone—hematologic cancer	3.82e-05	9.04e-05	CcSEcCtD
Ceftriaxone—Dermatitis—Prednisone—hematologic cancer	3.82e-05	9.03e-05	CcSEcCtD
Ceftriaxone—Headache—Prednisone—hematologic cancer	3.79e-05	8.98e-05	CcSEcCtD
Ceftriaxone—ALB—Metabolism of lipids and lipoproteins—ARNTL—hematologic cancer	3.79e-05	0.000547	CbGpPWpGaD
Ceftriaxone—Urticaria—Epirubicin—hematologic cancer	3.76e-05	8.91e-05	CcSEcCtD
Ceftriaxone—Pain—Doxorubicin—hematologic cancer	3.75e-05	8.88e-05	CcSEcCtD
Ceftriaxone—Body temperature increased—Epirubicin—hematologic cancer	3.74e-05	8.87e-05	CcSEcCtD
Ceftriaxone—Abdominal pain—Epirubicin—hematologic cancer	3.74e-05	8.87e-05	CcSEcCtD
Ceftriaxone—Hypersensitivity—Methotrexate—hematologic cancer	3.73e-05	8.83e-05	CcSEcCtD
Ceftriaxone—ALB—FOXA2 and FOXA3 transcription factor networks—AKT1—hematologic cancer	3.72e-05	0.000536	CbGpPWpGaD
Ceftriaxone—ALB—Transmembrane transport of small molecules—TUBB2A—hematologic cancer	3.72e-05	0.000536	CbGpPWpGaD
Ceftriaxone—ALB—Metabolism—GMPS—hematologic cancer	3.68e-05	0.00053	CbGpPWpGaD
Ceftriaxone—ALB—Metabolism—PHYH—hematologic cancer	3.68e-05	0.00053	CbGpPWpGaD
Ceftriaxone—ALB—Metabolism—FTCD—hematologic cancer	3.68e-05	0.00053	CbGpPWpGaD
Ceftriaxone—ALB—Metabolism of lipids and lipoproteins—NCOR2—hematologic cancer	3.64e-05	0.000525	CbGpPWpGaD
Ceftriaxone—ALB—Platelet degranulation—VEGFA—hematologic cancer	3.62e-05	0.000521	CbGpPWpGaD
Ceftriaxone—ALB—Folate Metabolism—TNF—hematologic cancer	3.61e-05	0.000521	CbGpPWpGaD
Ceftriaxone—ALB—Hemostasis—FGR—hematologic cancer	3.61e-05	0.000521	CbGpPWpGaD
Ceftriaxone—ALB—Hemostasis—H3F3B—hematologic cancer	3.61e-05	0.000521	CbGpPWpGaD
Ceftriaxone—Feeling abnormal—Doxorubicin—hematologic cancer	3.61e-05	8.55e-05	CcSEcCtD
Ceftriaxone—ALB—Platelet activation, signaling and aggregation—HGF—hematologic cancer	3.61e-05	0.000521	CbGpPWpGaD
Ceftriaxone—Nausea—Prednisone—hematologic cancer	3.6e-05	8.52e-05	CcSEcCtD
Ceftriaxone—ALB—Vitamin B12 Metabolism—IL6—hematologic cancer	3.58e-05	0.000517	CbGpPWpGaD
Ceftriaxone—Gastrointestinal pain—Doxorubicin—hematologic cancer	3.58e-05	8.49e-05	CcSEcCtD
Ceftriaxone—Pruritus—Methotrexate—hematologic cancer	3.58e-05	8.48e-05	CcSEcCtD
Ceftriaxone—ALB—Platelet activation, signaling and aggregation—CSF2—hematologic cancer	3.57e-05	0.000515	CbGpPWpGaD
Ceftriaxone—Hypersensitivity—Epirubicin—hematologic cancer	3.49e-05	8.26e-05	CcSEcCtD
Ceftriaxone—Urticaria—Doxorubicin—hematologic cancer	3.48e-05	8.24e-05	CcSEcCtD
Ceftriaxone—ALB—Hemostasis—ITGAL—hematologic cancer	3.48e-05	0.000501	CbGpPWpGaD
Ceftriaxone—ALB—Hemostasis—MYB—hematologic cancer	3.48e-05	0.000501	CbGpPWpGaD
Ceftriaxone—ALB—Metabolism of lipids and lipoproteins—IDH1—hematologic cancer	3.47e-05	0.0005	CbGpPWpGaD
Ceftriaxone—Body temperature increased—Doxorubicin—hematologic cancer	3.46e-05	8.2e-05	CcSEcCtD
Ceftriaxone—Abdominal pain—Doxorubicin—hematologic cancer	3.46e-05	8.2e-05	CcSEcCtD
Ceftriaxone—Diarrhoea—Methotrexate—hematologic cancer	3.46e-05	8.2e-05	CcSEcCtD
Ceftriaxone—ALB—Platelet activation, signaling and aggregation—PRKCG—hematologic cancer	3.45e-05	0.000497	CbGpPWpGaD
Ceftriaxone—ALB—Platelet activation, signaling and aggregation—JAK1—hematologic cancer	3.45e-05	0.000497	CbGpPWpGaD
Ceftriaxone—ALB—Response to elevated platelet cytosolic Ca2+—VEGFA—hematologic cancer	3.44e-05	0.000496	CbGpPWpGaD
Ceftriaxone—ALB—Metabolism of lipids and lipoproteins—ABCC3—hematologic cancer	3.43e-05	0.000495	CbGpPWpGaD
Ceftriaxone—GLUL—Metabolism—PIK3CG—hematologic cancer	3.4e-05	0.00049	CbGpPWpGaD
Ceftriaxone—ALB—Metabolism—SMPD3—hematologic cancer	3.37e-05	0.000485	CbGpPWpGaD
Ceftriaxone—ALB—Metabolism of lipids and lipoproteins—SPHK1—hematologic cancer	3.36e-05	0.000484	CbGpPWpGaD
Ceftriaxone—SLC22A11—Transmembrane transport of small molecules—CREBBP—hematologic cancer	3.35e-05	0.000483	CbGpPWpGaD
Ceftriaxone—Pruritus—Epirubicin—hematologic cancer	3.35e-05	7.94e-05	CcSEcCtD
Ceftriaxone—Dizziness—Methotrexate—hematologic cancer	3.35e-05	7.93e-05	CcSEcCtD
Ceftriaxone—ALB—Platelet degranulation—TGFB1—hematologic cancer	3.32e-05	0.000478	CbGpPWpGaD
Ceftriaxone—ALB—Hemostasis—RAC2—hematologic cancer	3.3e-05	0.000476	CbGpPWpGaD
Ceftriaxone—ALB—Transmembrane transport of small molecules—ABCC3—hematologic cancer	3.26e-05	0.00047	CbGpPWpGaD
Ceftriaxone—Diarrhoea—Epirubicin—hematologic cancer	3.24e-05	7.67e-05	CcSEcCtD
Ceftriaxone—Hypersensitivity—Doxorubicin—hematologic cancer	3.23e-05	7.65e-05	CcSEcCtD
Ceftriaxone—ALB—Platelet activation, signaling and aggregation—IL2RA—hematologic cancer	3.22e-05	0.000464	CbGpPWpGaD
Ceftriaxone—Vomiting—Methotrexate—hematologic cancer	3.22e-05	7.62e-05	CcSEcCtD
Ceftriaxone—SLC22A6—Transmembrane transport of small molecules—ABCB1—hematologic cancer	3.19e-05	0.00046	CbGpPWpGaD
Ceftriaxone—Rash—Methotrexate—hematologic cancer	3.19e-05	7.56e-05	CcSEcCtD
Ceftriaxone—Dermatitis—Methotrexate—hematologic cancer	3.19e-05	7.55e-05	CcSEcCtD
Ceftriaxone—ALB—Folate Metabolism—TP53—hematologic cancer	3.19e-05	0.000459	CbGpPWpGaD
Ceftriaxone—Headache—Methotrexate—hematologic cancer	3.17e-05	7.51e-05	CcSEcCtD
Ceftriaxone—ALB—Response to elevated platelet cytosolic Ca2+—TGFB1—hematologic cancer	3.16e-05	0.000456	CbGpPWpGaD
Ceftriaxone—GLUL—Metabolism—CREBBP—hematologic cancer	3.15e-05	0.000455	CbGpPWpGaD
Ceftriaxone—SLC22A11—Transmembrane transport of small molecules—ALB—hematologic cancer	3.14e-05	0.000452	CbGpPWpGaD
Ceftriaxone—ALB—Metabolism of lipids and lipoproteins—CRABP1—hematologic cancer	3.14e-05	0.000452	CbGpPWpGaD
Ceftriaxone—Dizziness—Epirubicin—hematologic cancer	3.13e-05	7.42e-05	CcSEcCtD
Ceftriaxone—ALB—Platelet activation, signaling and aggregation—PDGFB—hematologic cancer	3.11e-05	0.000448	CbGpPWpGaD
Ceftriaxone—Pruritus—Doxorubicin—hematologic cancer	3.1e-05	7.34e-05	CcSEcCtD
Ceftriaxone—SLC15A2—Transmembrane transport of small molecules—CREBBP—hematologic cancer	3.1e-05	0.000447	CbGpPWpGaD
Ceftriaxone—ALB—Metabolism of lipids and lipoproteins—ALOX5—hematologic cancer	3.06e-05	0.000441	CbGpPWpGaD
Ceftriaxone—Vomiting—Epirubicin—hematologic cancer	3.01e-05	7.13e-05	CcSEcCtD
Ceftriaxone—Nausea—Methotrexate—hematologic cancer	3.01e-05	7.12e-05	CcSEcCtD
Ceftriaxone—Diarrhoea—Doxorubicin—hematologic cancer	3e-05	7.1e-05	CcSEcCtD
Ceftriaxone—ALB—Hemostasis—SH2B3—hematologic cancer	2.99e-05	0.000432	CbGpPWpGaD
Ceftriaxone—GLUL—Metabolism—PIK3CD—hematologic cancer	2.99e-05	0.000431	CbGpPWpGaD
Ceftriaxone—Rash—Epirubicin—hematologic cancer	2.99e-05	7.07e-05	CcSEcCtD
Ceftriaxone—ALB—Transmembrane transport of small molecules—SLC22A1—hematologic cancer	2.98e-05	0.00043	CbGpPWpGaD
Ceftriaxone—Dermatitis—Epirubicin—hematologic cancer	2.98e-05	7.07e-05	CcSEcCtD
Ceftriaxone—Headache—Epirubicin—hematologic cancer	2.97e-05	7.03e-05	CcSEcCtD
Ceftriaxone—GLUL—Metabolism—ALB—hematologic cancer	2.95e-05	0.000425	CbGpPWpGaD
Ceftriaxone—ALB—Metabolism—ASNS—hematologic cancer	2.94e-05	0.000424	CbGpPWpGaD
Ceftriaxone—ALB—Metabolism—B3GAT1—hematologic cancer	2.94e-05	0.000424	CbGpPWpGaD
Ceftriaxone—ALB—Metabolism—DCK—hematologic cancer	2.94e-05	0.000424	CbGpPWpGaD
Ceftriaxone—ALB—Folate Metabolism—IL6—hematologic cancer	2.92e-05	0.00042	CbGpPWpGaD
Ceftriaxone—SLC15A2—Transmembrane transport of small molecules—ALB—hematologic cancer	2.9e-05	0.000418	CbGpPWpGaD
Ceftriaxone—Dizziness—Doxorubicin—hematologic cancer	2.9e-05	6.86e-05	CcSEcCtD
Ceftriaxone—ALB—Platelet activation, signaling and aggregation—MAPK14—hematologic cancer	2.89e-05	0.000417	CbGpPWpGaD
Ceftriaxone—ALB—Metabolism of lipids and lipoproteins—NCOA3—hematologic cancer	2.88e-05	0.000414	CbGpPWpGaD
Ceftriaxone—SLC15A1—Transmembrane transport of small molecules—CREBBP—hematologic cancer	2.88e-05	0.000414	CbGpPWpGaD
Ceftriaxone—ALB—Selenium Micronutrient Network—TNF—hematologic cancer	2.87e-05	0.000414	CbGpPWpGaD
Ceftriaxone—ALB—Hemostasis—SPARC—hematologic cancer	2.86e-05	0.000412	CbGpPWpGaD
Ceftriaxone—GLUL—Metabolism—PIK3R1—hematologic cancer	2.82e-05	0.000407	CbGpPWpGaD
Ceftriaxone—ALB—Transmembrane transport of small molecules—NUP98—hematologic cancer	2.82e-05	0.000406	CbGpPWpGaD
Ceftriaxone—Nausea—Epirubicin—hematologic cancer	2.81e-05	6.66e-05	CcSEcCtD
Ceftriaxone—ALB—Platelet activation, signaling and aggregation—FN1—hematologic cancer	2.8e-05	0.000404	CbGpPWpGaD
Ceftriaxone—ALB—Metabolism—HDC—hematologic cancer	2.79e-05	0.000402	CbGpPWpGaD
Ceftriaxone—Vomiting—Doxorubicin—hematologic cancer	2.79e-05	6.6e-05	CcSEcCtD
Ceftriaxone—ALB—Hemostasis—LCK—hematologic cancer	2.77e-05	0.000399	CbGpPWpGaD
Ceftriaxone—Rash—Doxorubicin—hematologic cancer	2.76e-05	6.54e-05	CcSEcCtD
Ceftriaxone—Dermatitis—Doxorubicin—hematologic cancer	2.76e-05	6.54e-05	CcSEcCtD
Ceftriaxone—Headache—Doxorubicin—hematologic cancer	2.75e-05	6.5e-05	CcSEcCtD
Ceftriaxone—ALB—Transmembrane transport of small molecules—ADCY7—hematologic cancer	2.73e-05	0.000394	CbGpPWpGaD
Ceftriaxone—ALB—Transmembrane transport of small molecules—NUP214—hematologic cancer	2.71e-05	0.000391	CbGpPWpGaD
Ceftriaxone—ALB—Hemostasis—H3F3A—hematologic cancer	2.71e-05	0.000391	CbGpPWpGaD
Ceftriaxone—SLC15A1—Transmembrane transport of small molecules—ALB—hematologic cancer	2.69e-05	0.000388	CbGpPWpGaD
Ceftriaxone—ALB—Hemostasis—GATA3—hematologic cancer	2.69e-05	0.000387	CbGpPWpGaD
Ceftriaxone—ALB—Platelet activation, signaling and aggregation—PIK3CG—hematologic cancer	2.68e-05	0.000387	CbGpPWpGaD
Ceftriaxone—ALB—Hemostasis—HSPA5—hematologic cancer	2.67e-05	0.000385	CbGpPWpGaD
Ceftriaxone—ALB—Transmembrane transport of small molecules—ABCG2—hematologic cancer	2.66e-05	0.000383	CbGpPWpGaD
Ceftriaxone—ALB—Hemostasis—PRKCZ—hematologic cancer	2.64e-05	0.00038	CbGpPWpGaD
Ceftriaxone—GLUL—Metabolism—PIK3CB—hematologic cancer	2.61e-05	0.000376	CbGpPWpGaD
Ceftriaxone—Nausea—Doxorubicin—hematologic cancer	2.6e-05	6.16e-05	CcSEcCtD
Ceftriaxone—ALB—Metabolism of lipids and lipoproteins—SDC1—hematologic cancer	2.6e-05	0.000375	CbGpPWpGaD
Ceftriaxone—SLC22A8—Transmembrane transport of small molecules—CREBBP—hematologic cancer	2.56e-05	0.000369	CbGpPWpGaD
Ceftriaxone—ALB—Metabolism—CDA—hematologic cancer	2.55e-05	0.000368	CbGpPWpGaD
Ceftriaxone—ALB—Hemostasis—HDAC2—hematologic cancer	2.46e-05	0.000354	CbGpPWpGaD
Ceftriaxone—ALB—Metabolism—PC—hematologic cancer	2.46e-05	0.000354	CbGpPWpGaD
Ceftriaxone—ALB—Hemostasis—ITGA4—hematologic cancer	2.43e-05	0.00035	CbGpPWpGaD
Ceftriaxone—ALB—Hemostasis—CD44—hematologic cancer	2.43e-05	0.00035	CbGpPWpGaD
Ceftriaxone—SLC22A8—Transmembrane transport of small molecules—ALB—hematologic cancer	2.39e-05	0.000345	CbGpPWpGaD
Ceftriaxone—ALB—Metabolism—GBA—hematologic cancer	2.37e-05	0.000342	CbGpPWpGaD
Ceftriaxone—ALB—Metabolism—SLC35B2—hematologic cancer	2.37e-05	0.000342	CbGpPWpGaD
Ceftriaxone—ALB—Transmembrane transport of small molecules—TFRC—hematologic cancer	2.37e-05	0.000342	CbGpPWpGaD
Ceftriaxone—ALB—Hemostasis—IL3—hematologic cancer	2.37e-05	0.000341	CbGpPWpGaD
Ceftriaxone—ALB—Platelet activation, signaling and aggregation—PIK3CD—hematologic cancer	2.36e-05	0.00034	CbGpPWpGaD
Ceftriaxone—ALB—Hemostasis—IFNA1—hematologic cancer	2.35e-05	0.000339	CbGpPWpGaD
Ceftriaxone—ALB—Hemostasis—PTPN1—hematologic cancer	2.33e-05	0.000336	CbGpPWpGaD
Ceftriaxone—ALB—Selenium Micronutrient Network—IL6—hematologic cancer	2.32e-05	0.000334	CbGpPWpGaD
Ceftriaxone—ALB—Hemostasis—RASGRP1—hematologic cancer	2.29e-05	0.00033	CbGpPWpGaD
Ceftriaxone—ALB—Hemostasis—SYK—hematologic cancer	2.28e-05	0.000329	CbGpPWpGaD
Ceftriaxone—GLUL—Metabolism—PTEN—hematologic cancer	2.25e-05	0.000325	CbGpPWpGaD
Ceftriaxone—ALB—Platelet activation, signaling and aggregation—PIK3R1—hematologic cancer	2.23e-05	0.000321	CbGpPWpGaD
Ceftriaxone—ALB—Hemostasis—IFNA2—hematologic cancer	2.19e-05	0.000316	CbGpPWpGaD
Ceftriaxone—ALB—Metabolism—MTAP—hematologic cancer	2.17e-05	0.000313	CbGpPWpGaD
Ceftriaxone—ALB—Platelet activation, signaling and aggregation—JAK2—hematologic cancer	2.16e-05	0.000312	CbGpPWpGaD
Ceftriaxone—GLUL—Metabolism—EP300—hematologic cancer	2.15e-05	0.00031	CbGpPWpGaD
Ceftriaxone—SLC22A6—Transmembrane transport of small molecules—CREBBP—hematologic cancer	2.13e-05	0.000308	CbGpPWpGaD
Ceftriaxone—ALB—Hemostasis—GRB2—hematologic cancer	2.06e-05	0.000297	CbGpPWpGaD
Ceftriaxone—ALB—Hemostasis—PDGFA—hematologic cancer	2.05e-05	0.000296	CbGpPWpGaD
Ceftriaxone—ALB—Platelet activation, signaling and aggregation—PIK3CB—hematologic cancer	2.05e-05	0.000296	CbGpPWpGaD
Ceftriaxone—SLC22A6—Transmembrane transport of small molecules—ALB—hematologic cancer	2e-05	0.000288	CbGpPWpGaD
Ceftriaxone—ALB—Transmembrane transport of small molecules—CYCS—hematologic cancer	1.99e-05	0.000287	CbGpPWpGaD
Ceftriaxone—ALB—Hemostasis—ABL1—hematologic cancer	1.98e-05	0.000285	CbGpPWpGaD
Ceftriaxone—ALB—Metabolism—FHL2—hematologic cancer	1.93e-05	0.000279	CbGpPWpGaD
Ceftriaxone—ALB—Metabolism—AGRN—hematologic cancer	1.9e-05	0.000273	CbGpPWpGaD
Ceftriaxone—ALB—Platelet activation, signaling and aggregation—IL2—hematologic cancer	1.89e-05	0.000272	CbGpPWpGaD
Ceftriaxone—ALB—Hemostasis—HGF—hematologic cancer	1.86e-05	0.000268	CbGpPWpGaD
Ceftriaxone—ALB—Hemostasis—CSF2—hematologic cancer	1.84e-05	0.000265	CbGpPWpGaD
Ceftriaxone—ALB—Metabolism—HMMR—hematologic cancer	1.8e-05	0.000259	CbGpPWpGaD
Ceftriaxone—ALB—Metabolism—IDH2—hematologic cancer	1.8e-05	0.000259	CbGpPWpGaD
Ceftriaxone—ALB—Hemostasis—PRKCG—hematologic cancer	1.78e-05	0.000256	CbGpPWpGaD
Ceftriaxone—ALB—Hemostasis—JAK1—hematologic cancer	1.78e-05	0.000256	CbGpPWpGaD
Ceftriaxone—ALB—Metabolism of lipids and lipoproteins—NCOR1—hematologic cancer	1.69e-05	0.000244	CbGpPWpGaD
Ceftriaxone—ALB—Metabolism—ARNTL—hematologic cancer	1.69e-05	0.000244	CbGpPWpGaD
Ceftriaxone—ALB—Transmembrane transport of small molecules—ABCB1—hematologic cancer	1.66e-05	0.000239	CbGpPWpGaD
Ceftriaxone—ALB—Hemostasis—IL2RA—hematologic cancer	1.66e-05	0.000239	CbGpPWpGaD
Ceftriaxone—ALB—Platelet activation, signaling and aggregation—SRC—hematologic cancer	1.65e-05	0.000237	CbGpPWpGaD
Ceftriaxone—ALB—Metabolism—CA9—hematologic cancer	1.64e-05	0.000237	CbGpPWpGaD
Ceftriaxone—ALB—Metabolism—ACP5—hematologic cancer	1.64e-05	0.000237	CbGpPWpGaD
Ceftriaxone—ALB—Metabolism—NCOR2—hematologic cancer	1.62e-05	0.000234	CbGpPWpGaD
Ceftriaxone—ALB—Platelet activation, signaling and aggregation—VEGFA—hematologic cancer	1.6e-05	0.000231	CbGpPWpGaD
Ceftriaxone—ALB—Hemostasis—PDGFB—hematologic cancer	1.6e-05	0.000231	CbGpPWpGaD
Ceftriaxone—GLUL—Metabolism—PIK3CA—hematologic cancer	1.59e-05	0.000229	CbGpPWpGaD
Ceftriaxone—ALB—Hemostasis—CDK2—hematologic cancer	1.55e-05	0.000224	CbGpPWpGaD
Ceftriaxone—ALB—Metabolism—IDH1—hematologic cancer	1.55e-05	0.000223	CbGpPWpGaD
Ceftriaxone—ALB—Metabolism—GSTO1—hematologic cancer	1.53e-05	0.00022	CbGpPWpGaD
Ceftriaxone—ALB—Metabolism—ABCC3—hematologic cancer	1.53e-05	0.00022	CbGpPWpGaD
Ceftriaxone—ALB—Metabolism—TXN—hematologic cancer	1.53e-05	0.00022	CbGpPWpGaD
Ceftriaxone—ALB—Platelet activation, signaling and aggregation—MAPK3—hematologic cancer	1.52e-05	0.000219	CbGpPWpGaD
Ceftriaxone—ALB—Metabolism—SPHK1—hematologic cancer	1.5e-05	0.000216	CbGpPWpGaD
Ceftriaxone—ALB—Hemostasis—MAPK14—hematologic cancer	1.49e-05	0.000215	CbGpPWpGaD
Ceftriaxone—ALB—Platelet activation, signaling and aggregation—TGFB1—hematologic cancer	1.47e-05	0.000212	CbGpPWpGaD
Ceftriaxone—ALB—Hemostasis—FN1—hematologic cancer	1.44e-05	0.000208	CbGpPWpGaD
Ceftriaxone—ALB—Metabolism—UGT1A1—hematologic cancer	1.44e-05	0.000207	CbGpPWpGaD
Ceftriaxone—ALB—Metabolism—CRABP1—hematologic cancer	1.4e-05	0.000201	CbGpPWpGaD
Ceftriaxone—ALB—Metabolism—SLC22A1—hematologic cancer	1.4e-05	0.000201	CbGpPWpGaD
Ceftriaxone—ALB—Hemostasis—PIK3CG—hematologic cancer	1.38e-05	0.000199	CbGpPWpGaD
Ceftriaxone—ALB—Metabolism—ALOX5—hematologic cancer	1.36e-05	0.000196	CbGpPWpGaD
Ceftriaxone—ALB—Hemostasis—PTPN11—hematologic cancer	1.36e-05	0.000196	CbGpPWpGaD
Ceftriaxone—ALB—Metabolism—NUP98—hematologic cancer	1.32e-05	0.00019	CbGpPWpGaD
Ceftriaxone—GLUL—Metabolism—AKT1—hematologic cancer	1.3e-05	0.000187	CbGpPWpGaD
Ceftriaxone—ALB—Hemostasis—CREBBP—hematologic cancer	1.28e-05	0.000185	CbGpPWpGaD
Ceftriaxone—ALB—Metabolism—ADCY7—hematologic cancer	1.28e-05	0.000185	CbGpPWpGaD
Ceftriaxone—ALB—Metabolism—NCOA3—hematologic cancer	1.28e-05	0.000185	CbGpPWpGaD
Ceftriaxone—ALB—Metabolism—NUP214—hematologic cancer	1.27e-05	0.000183	CbGpPWpGaD
Ceftriaxone—ALB—Metabolism of lipids and lipoproteins—PIK3CG—hematologic cancer	1.26e-05	0.000181	CbGpPWpGaD
Ceftriaxone—ALB—Platelet activation, signaling and aggregation—PIK3CA—hematologic cancer	1.25e-05	0.000181	CbGpPWpGaD
Ceftriaxone—ALB—Metabolism—MTR—hematologic cancer	1.25e-05	0.00018	CbGpPWpGaD
Ceftriaxone—ALB—Metabolism—ABCG2—hematologic cancer	1.25e-05	0.00018	CbGpPWpGaD
Ceftriaxone—ALB—Metabolism—ENO2—hematologic cancer	1.22e-05	0.000176	CbGpPWpGaD
Ceftriaxone—ALB—Hemostasis—PIK3CD—hematologic cancer	1.22e-05	0.000175	CbGpPWpGaD
Ceftriaxone—ALB—Metabolism—GSTT1—hematologic cancer	1.18e-05	0.000171	CbGpPWpGaD
Ceftriaxone—ALB—Metabolism of lipids and lipoproteins—CREBBP—hematologic cancer	1.17e-05	0.000168	CbGpPWpGaD
Ceftriaxone—ALB—Metabolism—SDC1—hematologic cancer	1.16e-05	0.000167	CbGpPWpGaD
Ceftriaxone—ALB—Hemostasis—PIK3R1—hematologic cancer	1.15e-05	0.000165	CbGpPWpGaD
Ceftriaxone—ALB—Hemostasis—JAK2—hematologic cancer	1.12e-05	0.000161	CbGpPWpGaD
Ceftriaxone—ALB—Transmembrane transport of small molecules—CREBBP—hematologic cancer	1.11e-05	0.00016	CbGpPWpGaD
Ceftriaxone—ALB—Metabolism of lipids and lipoproteins—PIK3CD—hematologic cancer	1.11e-05	0.000159	CbGpPWpGaD
Ceftriaxone—ALB—Hemostasis—PIK3CB—hematologic cancer	1.06e-05	0.000153	CbGpPWpGaD
Ceftriaxone—ALB—Metabolism of lipids and lipoproteins—PIK3R1—hematologic cancer	1.04e-05	0.000151	CbGpPWpGaD
Ceftriaxone—ALB—Platelet activation, signaling and aggregation—AKT1—hematologic cancer	1.02e-05	0.000147	CbGpPWpGaD
Ceftriaxone—ALB—Metabolism—NQO1—hematologic cancer	9.85e-06	0.000142	CbGpPWpGaD
Ceftriaxone—ALB—Metabolism—CD44—hematologic cancer	9.85e-06	0.000142	CbGpPWpGaD
Ceftriaxone—ALB—Hemostasis—IL2—hematologic cancer	9.73e-06	0.00014	CbGpPWpGaD
Ceftriaxone—ALB—Metabolism of lipids and lipoproteins—PIK3CB—hematologic cancer	9.64e-06	0.000139	CbGpPWpGaD
Ceftriaxone—ALB—Metabolism—CYCS—hematologic cancer	9.32e-06	0.000134	CbGpPWpGaD
Ceftriaxone—ALB—Metabolism—HSP90AA1—hematologic cancer	9.26e-06	0.000133	CbGpPWpGaD
Ceftriaxone—ALB—Hemostasis—EP300—hematologic cancer	8.73e-06	0.000126	CbGpPWpGaD
Ceftriaxone—ALB—Hemostasis—SRC—hematologic cancer	8.49e-06	0.000122	CbGpPWpGaD
Ceftriaxone—ALB—Metabolism of lipids and lipoproteins—PTEN—hematologic cancer	8.33e-06	0.00012	CbGpPWpGaD
Ceftriaxone—ALB—Hemostasis—VEGFA—hematologic cancer	8.27e-06	0.000119	CbGpPWpGaD
Ceftriaxone—ALB—Metabolism—GSTP1—hematologic cancer	8.21e-06	0.000118	CbGpPWpGaD
Ceftriaxone—ALB—Hemostasis—NRAS—hematologic cancer	8.17e-06	0.000118	CbGpPWpGaD
Ceftriaxone—ALB—Metabolism of lipids and lipoproteins—EP300—hematologic cancer	7.95e-06	0.000115	CbGpPWpGaD
Ceftriaxone—ALB—Hemostasis—MAPK3—hematologic cancer	7.82e-06	0.000113	CbGpPWpGaD
Ceftriaxone—ALB—Metabolism—ABCB1—hematologic cancer	7.77e-06	0.000112	CbGpPWpGaD
Ceftriaxone—ALB—Hemostasis—TGFB1—hematologic cancer	7.59e-06	0.000109	CbGpPWpGaD
Ceftriaxone—ALB—Metabolism—GSTM1—hematologic cancer	7.55e-06	0.000109	CbGpPWpGaD
Ceftriaxone—ALB—Metabolism—NCOR1—hematologic cancer	7.55e-06	0.000109	CbGpPWpGaD
Ceftriaxone—ALB—Hemostasis—KRAS—hematologic cancer	7.03e-06	0.000101	CbGpPWpGaD
Ceftriaxone—ALB—Metabolism—MTHFR—hematologic cancer	6.67e-06	9.61e-05	CbGpPWpGaD
Ceftriaxone—ALB—Hemostasis—PIK3CA—hematologic cancer	6.46e-06	9.31e-05	CbGpPWpGaD
Ceftriaxone—ALB—Hemostasis—TP53—hematologic cancer	6.25e-06	9e-05	CbGpPWpGaD
Ceftriaxone—ALB—Hemostasis—HRAS—hematologic cancer	5.97e-06	8.61e-05	CbGpPWpGaD
Ceftriaxone—ALB—Metabolism of lipids and lipoproteins—PIK3CA—hematologic cancer	5.88e-06	8.47e-05	CbGpPWpGaD
Ceftriaxone—ALB—Metabolism—PIK3CG—hematologic cancer	5.6e-06	8.08e-05	CbGpPWpGaD
Ceftriaxone—ALB—Hemostasis—AKT1—hematologic cancer	5.27e-06	7.6e-05	CbGpPWpGaD
Ceftriaxone—ALB—Metabolism—CREBBP—hematologic cancer	5.2e-06	7.49e-05	CbGpPWpGaD
Ceftriaxone—ALB—Metabolism—PIK3CD—hematologic cancer	4.93e-06	7.1e-05	CbGpPWpGaD
Ceftriaxone—ALB—Metabolism—PIK3R1—hematologic cancer	4.65e-06	6.71e-05	CbGpPWpGaD
Ceftriaxone—ALB—Metabolism—PIK3CB—hematologic cancer	4.29e-06	6.19e-05	CbGpPWpGaD
Ceftriaxone—ALB—Metabolism—PTEN—hematologic cancer	3.71e-06	5.35e-05	CbGpPWpGaD
Ceftriaxone—ALB—Metabolism—EP300—hematologic cancer	3.54e-06	5.1e-05	CbGpPWpGaD
Ceftriaxone—ALB—Metabolism—PIK3CA—hematologic cancer	2.62e-06	3.77e-05	CbGpPWpGaD
Ceftriaxone—ALB—Metabolism—AKT1—hematologic cancer	2.14e-06	3.08e-05	CbGpPWpGaD
